Literature DB >> 26770519

Efficacy of medical thoracoscopic talc pleurodesis in malignant pleural effusion caused by different types of tumors and different pathological classifications of lung cancer.

Juan Chen1, Zhu Li2, Ning Xu3, Xin Zhang2, Yu Wang2, Dianjie Lin4.   

Abstract

The aim of this study was to assess the efficacy and complications and compare the efficacy of medical thoracoscopic talc pleurodesis among patients with different types of tumors and different pathological classifications of lung cancer as well as to evaluate the role of postoperative negative pressure chest tube drainage. A total of 1061 patients with malignant pleural effusion who underwent thoracoscopic pleurodesis were analyzed retrospectively. The complications, postoperative drainage time, and efficacy of pleurodesis among patients with different types of tumors and different pathological classifications of lung cancer were assessed. The overall response rate (ORR) was 88.03%. Major complications included chest pain (68%) and fever (47%). The postoperative drainage time was 4.74 ± 1.56 days. Postoperative negative pressure chest tube drainage significantly shortened the drainage time (negative vs. non-negative: 4.56 ± 1.49 days vs. 4.81 ± 1.59 days, P = 0.037). Pleurodesis was less effective in treating effusion caused by lung cancer (72.3%) and mesothelioma (68.2%) than that caused by breast cancer (84.4%) and other tumors (87.8%) (P = 0.009). The efficacy in the treatment of effusion caused by adenocarcinoma (66.7%) was slightly less than that caused by other types of lung cancer (P = 0.311). In conclusion, medical thoracoscopic talc pleurodesis is a palliative and effective treatment for malignant pleural effusion. In addition, postoperative simple negative pressure chest tube drainage significantly shortens the drainage time. However, thoracoscopic pleurodesis is less effective for the treatment of effusion caused by lung cancer and pleural mesothelioma compared with that caused by other types of cancers.

Entities:  

Keywords:  Malignant pleural effusion; cancer; medical thoracoscopy; pleurodesis

Year:  2015        PMID: 26770519      PMCID: PMC4694419     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  24 in total

1.  Management of malignant pleural effusions.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-11       Impact factor: 21.405

2.  Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study.

Authors:  Alessandro Stefani; Pamela Natali; Christian Casali; Uliano Morandi
Journal:  Eur J Cardiothorac Surg       Date:  2006-12       Impact factor: 4.191

3.  Thoracoscopy talc poudrage : a 15-year experience.

Authors:  J R de Campos; F S Vargas; E de Campos Werebe ; P Cardoso; L R Teixeira; F B Jatene; R W Light
Journal:  Chest       Date:  2001-03       Impact factor: 9.410

4.  Small particle-size talc is associated with poor outcome and increased inflammation in thoracoscopic pleurodesis.

Authors:  Elena Arellano-Orden; Auxiliadora Romero-Falcon; José Martin Juan; Manuel Ocaña Jurado; Francisco Rodriguez-Panadero; Ana Montes-Worboys
Journal:  Respiration       Date:  2012-09-27       Impact factor: 3.580

5.  Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions.

Authors:  Steffen Kolschmann; Arndt Ballin; Adrian Gillissen
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

6.  Video-assisted talc pleurodesis for malignant pleural effusions utilizing local anesthesia and I.V. sedation.

Authors:  C A Danby; S A Adebonojo; D M Moritz
Journal:  Chest       Date:  1998-03       Impact factor: 9.410

7.  Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients.

Authors:  M Schulze; A S Boehle; R Kurdow; P Dohrmann; D Henne-Bruns
Journal:  Ann Thorac Surg       Date:  2001-06       Impact factor: 4.330

8.  Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases.

Authors:  Nikolaos Barbetakis; Christos Asteriou; Fani Papadopoulou; Georgios Samanidis; Dimitrios Paliouras; Athanassios Kleontas; Konstantina Lyriti; Ioannis Katsikas; Christodoulos Tsilikas
Journal:  J Cardiothorac Surg       Date:  2010-04-19       Impact factor: 1.637

9.  Tumor type influences the effectiveness of pleurodesis in malignant effusions.

Authors:  Silvia Bielsa; Paula Hernández; Francisco Rodriguez-Panadero; Teresa Taberner; Antonieta Salud; José M Porcel
Journal:  Lung       Date:  2011-02-18       Impact factor: 2.584

10.  Can intrapleural C-reactive protein predict VATS pleurodesis failure?

Authors:  F Leo; N Vénissac; D Pop; A Rosenthal-Allieri; J Mouroux
Journal:  Thorac Cardiovasc Surg       Date:  2006-10       Impact factor: 1.827

View more
  1 in total

Review 1.  Proton beam therapy for malignant pleural mesothelioma.

Authors:  Shahed N Badiyan; Jason K Molitoris; Mingyao Zhu; Erica Glass; Tejan Diwanji; Charles B Simone
Journal:  Transl Lung Cancer Res       Date:  2018-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.